Is there an optimal adjunct therapy to traditional cytotoxic induction?. Issue 4 (December 2021)

• Record Type: Journal Article
• Authors: Michaelis, Laura C.
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 34:Issue 4(2021)
• Publication Date: 2021-12
• Subjects: Acute myeloid leukemia (AML) -- Cytarabine -- Daunorubicin -- Idarubicin -- Clofarabine -- Cladribine -- Gemtuzumab -- Midostaurin -- Lomustine; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2021.101326
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: The traditional cytotoxic induction regimen for acute myeloid leukemia (AML) is seven days of standard-dose cytarabine and three days of an anthracycline antibiotic (such as daunorubicin or idarubicin), commonly known as "7 + 3." Many studies have been conducted to find an additional agent that might improve efficacy. Data from select studies has shown, in certain populations, benefit to adding cladribine, clofarabine and lomustine to a traditional backbone. For mutation-based chemotherapy regimens, midostaurin with 7 + 3 is the current standard of care for FLT3-mutant, younger AML patients. As we learn more about the synergism of molecular agents and traditional anti-cancer treatments, we can hopefully develop novel regimens without abandoning some of the benefits of these mutation agnostic historical therapies.